Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-543 dosing regimens in alopecia areata
NCT03941548Phase 2Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- May 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of deuruxolitinib in alopecia areata (2 arms), sponsored by Concert Pharmaceuticals. Primary endpoint: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at 24 weeks. Started May 2019; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03941548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941548.